サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1480391

マウスモデルの世界市場

Mice Model
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 173 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円
マウスモデルの世界市場
出版日: 2024年05月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 173 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

マウスモデルの世界市場は2030年までに26億米ドルに達する見込み

2023年に19億米ドルと推定されるマウスモデルの世界市場は、2023～2030年の分析期間においてCAGR 5.2%で成長し、2030年には26億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるCRISPR/CAS9テクノロジーは、CAGR 6.5%を記録し、分析期間終了までに9億7,670万米ドルに達すると予測されます。マイクロインジェクション技術セグメントは、今後7年間のCAGRが4.3%と予測されています。

米国市場は4億9,000万米ドルと推定、中国はCAGR 8.1％で成長予測

米国のマウスモデル市場は、2023年には4億9,000万米ドルになると推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 8.1%で推移し、2030年には6億310万米ドルの市場規模に達すると予測されています。その他の注目すべき地理的市場としては、日本とカナダがあり、それぞれ2023年から2030年にかけて2.6%と4.8%の成長が予測されています。欧州では、ドイツがCAGR約3.1%で成長すると予測されています。オーストラリア、インド、韓国などの国々が牽引するアジア太平洋地域の市場は、2030年までに3億6,800万米ドルに達すると予測されています。

2024 年の魅力的な新しいレポート機能のご紹介

インフルエンサーのエンゲージメント統計へのフルアクセス

デジタルアーカイブと「MarketGlass」調査プラットフォームへの無料アクセス。当社独自のMarketGlassプラットフォームは、世界中の専門家の創造性と市場知識を統合的かつ協調的に解き放つことができます。当社の最先端のツールは、市場参入企業のプライバシーとアイデンティティを保護しながら、世界クラスの市場展望をもたらします。レポート内の数字、統計、市場に関する説明は、この分野の専門家や影響力のある人々によって共有された、完全にキュレートされた洞察に基づいています。

リアルタイムのデータシミュレーター・ツールや特注のレポート作成機能を備えたインタラクティブなアンケートに参加できます。

企業間のスマートな意見交換のためのピアコラボレーティブ・インタラクティブプラットフォームへのフルクライアントアクセス

1年間の無料レポート更新

主要プレーヤーの世界市場シェアを含む競合カバレッジ

複数の地域にまたがるプレーヤーの市場プレゼンス分析（好調/活発/ニッチ/マイナー）

専門家/インフルエンサーのインタビュー、ポッドキャスト、報道発表、イベント基調講演のYouTubeビデオへのアクセス

2024年の世界経済に期待すること

金融引き締めとそれに伴う金利上昇によって引き起こされる地政学的、経済的不安定性が、2024年の激動の情勢を作り出すと思われます。中東での敵対行為や、ますます頻発する気候災害など、いくつかの要因が回復への道筋に圧力をかけ続けると思われます。リスクの一方で、ディスインフレの兆候が強まり、頑迷なインフレに対する不安が緩和され、サプライチェーンが正常化し、エネルギーコストの変動にもかかわらず物価が緩やかになるなど、いくつかのプラス材料も具体化しつつあります。インドや米国をはじめとするG21諸国の選挙は、資本の流れや投資戦略に影響を与える可能性があります。インドが世界な投資先として注目される一方で、米国を拠点とするハイテク企業は、才能と資本のダイナミックなエコシステムに後押しされ、引き続き優位を保つと思われます。シリコンバレーをはじめとするハイテク機会は、国内経済が減速しているとはいえ底堅く、規制環境も整備されていることから、高成長の可能性を求める投資家にとって引き続き魅力的です。欧州は金融引き締め政策と景気後退リスクとの戦いが続くが、英国は見通しが最も厳しく、2024年の景気後退リスクが最も高いです。中国は、政府支出と個人消費の改善に支えられた成長が期待されるもの、引き続きワイルドカードとなります。不安定な環境は、投資家にも企業にもチャンスと課題の両方をもたらすと思われます。成長への触媒としてボラティリティを受け入れるとともに、敏捷性と戦略的な先見性をもって投資判断に臨むことが、生き残りのために重要であることに変わりはないです。

調査対象企業の例（全46件）

  • Charles River Laboratories International, Inc.
  • Envigo, Inc.
  • Genoway S.A.
  • Harbour Antibodies BV
  • Horizon Discovery Group PLC
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs
  • Laboratory Corporation of America Holdings（LabCorp）
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • Trans Genic, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP13287

Global Mice Model Market to Reach $2.6 Billion by 2030

The global market for Mice Model estimated at US$1.9 Billion in the year 2023, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. CRISPR / CAS9 Technology, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$976.7 Million by the end of the analysis period. Growth in the Microinjection Technology segment is estimated at 4.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $490 Million, While China is Forecast to Grow at 8.1% CAGR

The Mice Model market in the U.S. is estimated at US$490 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$603.1 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 4.8% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$368 Million by the year 2030.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 46 Featured) -

  • Charles River Laboratories International, Inc.
  • Envigo, Inc.
  • Genoway S.A.
  • Harbour Antibodies BV
  • Horizon Discovery Group PLC
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs
  • Laboratory Corporation of America Holdings (LabCorp)
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • Trans Genic, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Mice Model - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Microinjection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Microinjection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Embryonic Stem Cell Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Embryonic Stem Cell Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Nuclear Transfer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Nuclear Transfer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Breeding by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Breeding by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cryopreservation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cryopreservation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Mice Model Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for CRISPR / CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for CRISPR / CAS9 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for CRISPR / CAS9 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Quarantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Quarantine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Quarantine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Model-In Licensing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Model-In Licensing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Model-In Licensing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: World 16-Year Perspective for Central Nervous System (CNS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Immunology & Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Immunology & Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: World 16-Year Perspective for Immunology & Inflammation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: World 16-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: World 16-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: USA 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • JAPAN
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • CHINA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: China 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: China 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: China 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • EUROPE
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Mice Model by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • FRANCE
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: France 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: France 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: France 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • GERMANY
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Germany 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Germany 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Italy 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Italy 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Italy 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: UK 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: UK 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: UK 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Spain 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Spain 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Spain 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Russia 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Russia 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Russia 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Europe 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Europe 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Europe 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Mice Model by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Asia-Pacific 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Asia-Pacific 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Asia-Pacific 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Asia-Pacific 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Australia 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Australia 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 185: Australia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Australia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Australia 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • INDIA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 188: India Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: India 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 191: India Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: India 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 194: India Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: India Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: India 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: South Korea 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: South Korea 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 203: South Korea Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: South Korea Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: South Korea 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Asia-Pacific Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Asia-Pacific 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Mice Model by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Latin America 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Latin America 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Latin America 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 224: Latin America Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Latin America Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Latin America 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Argentina 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Argentina 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 233: Argentina Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Argentina Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Argentina 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Brazil 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Brazil 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 242: Brazil Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Brazil Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Brazil 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Mexico 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Mexico 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 251: Mexico Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Mexico Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Mexico 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Rest of Latin America 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Rest of Latin America 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Rest of Latin America Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Rest of Latin America 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Mice Model by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Middle East 16-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Middle East 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Middle East 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 272: Middle East Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Middle East Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Middle East 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Iran 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Iran 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 281: Iran Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Iran Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: Iran 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: Israel 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: Israel 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 290: Israel Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Israel Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: Israel 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Saudi Arabia 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Saudi Arabia 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Saudi Arabia Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Saudi Arabia 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: UAE 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: UAE 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 308: UAE Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 309: UAE Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 310: UAE 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 313: Rest of Middle East 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 316: Rest of Middle East 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 318: Rest of Middle East Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 319: Rest of Middle East 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030
  • AFRICA
    • Mice Model Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Mice Model by Technology - CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 322: Africa 16-Year Perspective for Mice Model by Technology - Percentage Breakdown of Value Sales for CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Mice Model by Service - Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 325: Africa 16-Year Perspective for Mice Model by Service - Percentage Breakdown of Value Sales for Breeding, Cryopreservation, Genetic Testing, Quarantine, Model-In Licensing and Other Services for the Years 2014, 2024 & 2030
    • TABLE 326: Africa Recent Past, Current & Future Analysis for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 327: Africa Historic Review for Mice Model by Therapeutic Area - Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 328: Africa 16-Year Perspective for Mice Model by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Central Nervous System (CNS), Immunology & Inflammation, Diabetes, Cardiovascular and Other Therapeutic Areas for the Years 2014, 2024 & 2030

IV. COMPETITION